Danaher names Daniel Comas, Robert Hershberg to board of directors

By Public Technologies
  • Danaher appointed Daniel L. Comas and Robert Hershberg to its board on Oct. 9, 2026.
  • Board expanded to 13 directors from 11 to accommodate the appointments.
  • Hershberg joined the Science and Technology Committee; he previously led HilleVax as CEO and chairman through September 2025.
  • Comas served as Danaher executive vice president from 2005 to 2020, including CFO from 2005 to 2018.
  • Director Alan G. Spoon will not stand for reelection at the 2027 annual meeting, retiring from the board then.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Danaher Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610121625PR_NEWS_USPR_____PH70271) on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.